In addition, limited evidence suggests that 5‐HT7 antagonists could enhance cognitive performance; however, more research is needed to establish their efficacy in AD and associated neuropsychiatric disorders [97, 98]. This evidence concerns the gene HTR7 and Alzheimer disease.